

# State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women

Sonali D. Advani,<sup>1</sup> Joshua T. Thaden,<sup>1</sup> Reinaldo Perez,<sup>1</sup> Sabrina L. Stair,<sup>2</sup> Una J. Lee,<sup>2</sup> and Nazema Y. Siddiqui<sup>3</sup>

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; <sup>2</sup>Section of Urology and Renal Transplantation, Virginia Mason Franciscan Health, Seattle, Washington, USA; and <sup>3</sup>Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina, USA

Over 50% of adult women experience at least 1 urinary tract infection (UTI) in their lifetime, and almost one-quarter of them will experience a recurrent UTI (rUTI). Recurrent UTI is defined as  $\geq 2$  UTIs in a 6-month period or  $\geq 3$  UTIs in 12 months (at least 1 of these episodes should be culture-proven to confirm infectious etiology). In this narrative review, we discuss the epidemiology, pathogenesis, diagnosis, and treatment considerations for recurrent uncomplicated cystitis in the adult female population. We provide a focused overview of the comprehensive management of these patients, with input from infectious disease physicians, urogynecologists, and urologists with expertise in rUTI, highlighting updated recommendations by the Infectious Diseases Society of America, American Urologic Association, Canadian Urologic Association, and American Urogynecologic Society. Finally, given the variety of prevention strategies, different treatment goals, and the need for “preference sensitive” decisions, we highlight the need for shared decision-making with patients.

**Keywords.** recurrent UTI; recurrent cystitis; LUTS; asymptomatic bacteriuria; chronic UTI.

Urinary tract infections (UTIs) are one of the most common infections encountered in both inpatient and outpatient health-care settings [1]. Over 50% of adult women experience at least 1 UTI in their lifetime, and almost one-quarter of them will experience a recurrent UTI (rUTI) [2–5].

Recurrent UTI is defined as 2 or more UTIs in a 6-month period or 3 or more UTIs in 12 months [6]. At least 1 of these infections should be culture-proven to confirm infectious etiology. While patients may recover fully from each UTI episode, the cumulative burden of rUTIs on healthcare costs and quality of life is substantial. Each UTI episode has, on average, 6.1 days of symptoms, 2.4 days of reduced activity, and 1.2 days of work or study lost [7]. Testing with formal quality-of-life instruments such as the RAND 36-Item Short Form Survey (SF-36) has shown that quality-of-life indices in all subsections are significantly decreased in patients with rUTIs [8, 9].

In this narrative review, we discuss the epidemiology, pathogenesis, diagnosis, and treatment considerations for recurrent uncomplicated cystitis in the adult female population. Data on

transgender populations are lacking, and we will use the terminology “women” to inclusively refer to those with female anatomy. Furthermore, the impact of race, ethnicity, and socioeconomic factors is poorly understood as most studies involve White female patients or, in many instances, demographics are not reported [10]. We provide a focused overview of the comprehensive management of these patients with input from infectious disease physicians, urogynecologists, and urologists with expertise in rUTI, highlighting updated recommendations by the Infectious Diseases Society of America, American Urologic Association (AUA), Canadian Urologic Association (CUA), and American Urogynecologic Society. Finally, we offer suggestions for patient–clinician shared decision-making. This review is written from the perspective of US-based clinicians and intended primarily for infectious disease specialists.

## EPIDEMIOLOGY OF rUTI

In a study of college-aged women with a single UTI, 19%–27% experienced recurrence within 6 months, while a study of Danish women aged 16–65 years showed a higher prevalence of recurrence between 25% and 35% within 3–6 months [11, 12]. The risk of rUTI among women varies by age, as there is approximately a 2-fold increased prevalence in postmenopausal women relative to premenopausal women [1, 13].


In premenopausal women, risk factors include sexual activity and spermicide-containing contraceptives [14, 15]. Genetic factors also seem to play a role. A history of a first UTI occurring before 15 years of age, maternal history of UTI, and having first-degree female relatives with rUTI are independent risk

Received 15 June 2024; editorial decision 31 July 2024

Correspondence: S. Advani, Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, 315 Trent Drive, Hanes House, Room 154, Durham, NC 27710 (sonali.advani@duke.edu).

Clinical Infectious Diseases® 2025;80(3):e31–42

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.  
<https://doi.org/10.1093/cid/ciae653>



factors for recurrence [5]. Variations in the innate immune response, including polymorphisms in the Toll-like receptors that recognize pathogens in the urinary tract, are associated with adult susceptibility to rUTI [5, 16].

In postmenopausal women, urinary incontinence, premenopausal history of UTI, residual urine after voiding, and nonsecretor status (ie, those with the autosomal recessive trait that do not secrete blood group antigens into urine and bodily fluids) have been associated with rUTI in case-control studies [17, 18]. Vulvovaginal atrophy and changes in the urinary microbiome, both stemming from the physiological changes of menopause, are significant contributors to increasing rUTI in peri- and postmenopausal women. After menopause, decreased estrogen levels within the urogenital epithelium results in decreased *Lactobacillus* colonization, leaving the area more vulnerable to pathogens [17, 18].

### **PATHOPHYSIOLOGY OF rUTI AND EMERGING KNOWLEDGE IN THE MODERN ERA**

Uropathogens are most commonly enteric gram-negative bacteria that have acquired the requisite virulence factors to thrive in the urinary environment. Historically, UTIs were thought to begin with pathogenic bacteria, usually originating from the gut or rectal area, colonizing the urethra and ascending into the bladder to cause infection [19]. Due to this thinking, clinicians have focused on eradicating “harmful bacteria” when found in the urine. However, we now know that pathogenic bacteria can be identified in the absence of urinary symptoms, either as asymptomatic bacteriuria on a standard urine culture or in low levels as part of the urinary microbiome [20]. As such, our understanding of rUTI pathogenesis has evolved [20]. In 1 model, there are repeated episodes of ascending infection from reservoirs outside of the urinary tract, which may include the vagina, vaginal microbiota, or gastrointestinal tract [21]. In another model, there is re-emergence of persistent intracellular bacterial colonies residing within the urinary tract itself [22, 23]. While both models may be true, the local ecology of other members of the urinary microbiome as well as host immune factors likely interact in both models of disease, leading to a multifactorial etiology of rUTIs (Figure 1) [22]. But, regardless of the cause of resulting bacteriuria, treatment is usually indicated for bacteriuria in symptomatic patients.

### **KEY COMPONENTS IN EVALUATION OF PATIENTS WITH rUTI**


Management of recurrent episodes of uncomplicated cystitis in women involves a stepwise approach (as shown in Figure 2) starting with (1) initial evaluation of the acute UTI episode, (2) distinguishing rUTI from relapse, (3) treatment of the acute UTI episode, and (4) prevention of future episodes. In 2019, The AUA in conjunction with the CUA and the Society for

Urodynamics and Female Urology (SUFU) published guidelines for the evaluation and management of rUTI in women [6]. These guidelines were most recently updated in 2022. The recommendations below are directed towards an otherwise healthy adult female with an uncomplicated rUTI.

#### **Initial Evaluation of Acute UTI Episode in Patients Meeting Criteria for rUTI**

An acute episode of cystitis is diagnosed primarily based on signs and symptoms localizing to the genitourinary tract [19, 24, 25]. The probability of cystitis is higher than 90% in women with dysuria and frequency in the absence of vaginal discharge or irritation (which may suggest other vulvovaginal entities) [19]. The initial evaluation of women with rUTI includes a focused history and physical examination to assess symptoms and frequency of infections, including UTI diagnostic testing results when available. Symptoms localizing to the genitourinary tract, such as dysuria, urinary frequency, urgency, suprapubic or flank pain, hematuria, and fever, should be documented, along with their duration and response to therapy [24]. Patients often attribute foul-smelling or cloudy urine to UTI; however, these symptoms are nonspecific for UTI, especially in the absence of other symptoms localizing to the genitourinary tract. Older women, especially those with frailty, may present with acute onset of general fatigue and/or confusion in the setting of pyuria and bacteriuria; however, antibiotic treatment is not recommended in the absence of localizing or systemic signs of infection [25]. The presence of fever, chills, rigors, marked fatigue, or malaise suggests that the infection has extended beyond the bladder and is regarded as acute complicated UTI [26]. The number and frequency of complicated and uncomplicated cystitis episodes should be determined.

Additionally, in patients meeting criteria for rUTI ( $\geq 2$  UTIs in 6 months or  $\geq 3$  UTIs in 12 months), clinicians should document which diagnostic testing was used for symptomatic episodes. Urinalysis is used in many ambulatory settings and may support the diagnosis in those with urinary symptoms, but the presence of pyuria or nitrites is not diagnostic of UTI in otherwise asymptomatic patients. Similarly, in the absence of genitourinary symptoms, positive urine cultures do not require antibiotic therapy [25]. Notably, the absence of pyuria can rule out UTI in most nonneutropenic patients [27]. For those with recurrent symptoms, it is beneficial to order a urine culture to help direct antimicrobial therapy and differentiate rUTI from other genitourinary conditions that mimic UTI, such as overactive bladder, painful bladder syndromes like interstitial cystitis, vulvovaginal entities, or genitourinary syndrome of menopause, which are treated with different modalities [6, 28]. Even though urine culture thresholds greater than 100 000 colony-forming units (CFU)/mL are used for diagnosis of UTI, bacterial counts over 1000 CFU/mL may be diagnostic of UTI in a symptomatic woman [29, 30]. If, when cultured, clean catch urine is contaminated or grows mixed



**Figure 1.** Evolving model of pathogenesis of uncomplicated recurrent urinary tract infection (showing re-emergence of persistent intracellular bacterial colonies residing within the urinary tract).


flora, then obtaining a catheterized urine specimen should be considered [6].

For women seeking initial evaluation for rUTI, we suggest asking probing questions to assess for other genitourinary conditions that present with symptoms similar to rUTI (eg, genitourinary atrophy, urethral diverticulum or strictures, bladder outlet obstruction, and vaginal prolapse). If symptoms are present, unclear, or uncertain, then the physical examination should include pelvic examination [6, 28]. As studies have shown that adequate bladder emptying is important for UTI prevention [31], assessment of bladder emptying should be considered, particularly in older women and those with neurologic disease, diabetes, vaginal prolapse, or symptoms of incomplete bladder emptying. We suggest asking probing questions to assess for urinary hesitancy and incomplete or interrupted bladder emptying. If symptoms are present or uncertain, bladder emptying can be assessed by checking the post-void residual (PVR) using either urethral catheterization or bladder scan within 30 minutes of a void. In neurologically intact women, a PVR above 150 mL is abnormal. In patients

with neurogenic bladder, retained urine of more than 300 mL has been associated with a 4-fold risk of UTI [32]. Most women with rUTI do not warrant imaging or urologic evaluation (eg, cystoscopy or upper tract imaging) unless their symptoms do not improve with appropriate treatment, or unless their history or physical examination suggests structural or functional abnormalities of the genitourinary tract [33]. If these risk factors are suspected or diagnosed, a referral to urology or a urogynecologist would be beneficial for further management.

#### Distinguishing rUTI From Relapse

The next step is to determine if this acute episode represents recurrence or relapse. Clinically, relapse is classified as a recurrent episode within 2 weeks of a previous UTI, suggesting either failure of the antimicrobial therapy or a persisting nidus of infection. These patients need a repeat urine culture to assess for pathogen–drug mismatch and may need further evaluation for anatomical or functional abnormalities of the urinary tract [5].




**Figure 2.** Stepwise approach to evaluation of recurrent urinary tract infection (rUTI). \*If urine culture is contaminated or has mixed flora growth, repeat urine culture using straight catheterization (if symptoms still present). In rare cases, patients with negative urine culture may need additional urine testing with advanced molecular methods.

### Treatment of an Acute rUTI Episode

In patients meeting criteria for rUTI ( $\geq 2$  UTIs in 6 months or  $\geq 3$  in 1 year) and presenting with acute genitourinary symptoms, treatment should generally use first-line antibiotic therapy, in keeping with the local antibiogram, prior culture and sensitivity results, recent antibiotic use, and prioritizing a quinolone-sparing approach [5]. However, a watch-and-wait strategy could be offered to some patients with prescription

for empiric antibiotics should symptoms persist or worsen while awaiting culture [34]. We suggest using a shared decision-making approach and leveraging a patient decision aid to discuss pros and cons of empiric antibiotics versus a watch-and-wait strategy [34]. If empiric therapy is used initially, it should be subsequently tailored according to urine culture results or clinical response. The duration of antibiotic regimens is the same as those used for sporadic uncomplicated



**Figure 3.** Prevention strategy for recurrent urinary tract infection (rUTI).

cystitis [5]. If symptoms resolve, a “proof of cure” culture is not necessary. If genitourinary symptoms persist after treatment or systemic symptoms develop, a repeat urinalysis (UA) and urine culture should be obtained [6, 35]. At this point, further evaluation to assess for structural or functional abnormalities of the genitourinary tract may be needed, if not already performed.

#### Strategies to Prevent Future Recurrence

After resolution of the acute UTI episode, the next step is to prevent further recurrences (Figure 3). There are multiple prevention strategies to prevent rUTIs, as shown in Table 1. These can be broadly broken down into the following: (1) behavioral strategies, (2) non-antimicrobial strategies, and (3) antimicrobial prevention strategies. Based on patient factors and patient preferences, behavioral and non-antimicrobial strategies should be optimized prior to pursuing antimicrobial strategies [36]. However, the timing and frequency of recent infections

often guide the initial prevention strategy, with more frequent or higher acuity infections often requiring antimicrobial strategies initially. In many instances, several strategies are combined to help the local microenvironment, and to facilitate antimicrobial-sparing strategies long-term.

#### Behavioral Strategies

Increased hydration has been shown to prevent rUTIs, by increasing dilution and flushing of bacteria from the bladder. In a 2018 randomized controlled trial (RCT), women with rUTIs were assigned to drink an additional 1.5 L of water per day. During the 12-month study period, the mean number of cystitis episodes was 1.7 (95% confidence interval [CI]: 1.4–1.8) in the water group compared to 3.2 (95% CI: 3.0–3.4) in the control group, with a significant difference in mean UTIs of 1.5 (95% CI: 1.2–1.8;  $P < .001$ ). The authors noted that, although increased hydration is not equivalent to daily antibiotic

**Table 1. Prevention Strategies for Recurrent Urinary Tract Infection**

	Strategies
<b>Behavioral strategies</b>	
Hydration	2–3 L of water daily
Pelvic floor physical therapy	If pelvic floor dysfunction causing incomplete voiding
<b>Non-antimicrobial strategies<sup>a</sup></b>	
Vaginal estrogen	0.1 mg/g cream every night × 2 wk, then 2x weekly 4 or 10 µg suppository every night × 2 wk, then 2x weekly 2 mg/g ring (standard dose: 7.5 µg/24 h); change ring every 3 mo (off-label approach)
Cranberry	36–72 soluble PACs per day
Methenamine	1 g twice daily
D-Mannose	500 mg 1 to 3 times daily
<b>Antibiotic prevention strategies<sup>a</sup></b>	
Postcoital (single dose)	PO nitrofurantoin 50 mg or 100 mg Trimethoprim/sulfamethoxazole 40/200 mg or 80 mg/400mg PO trimethoprim 100 mg PO cephalexin 250 mg
Low-dose continuous prophylaxis	PO nitrofurantoin 50 mg daily or 100 mg daily PO trimethoprim/sulfamethoxazole 40/200 mg daily or 3 times weekly PO trimethoprim 100 mg daily PO cephalexin 125 mg or 250 mg daily

Abbreviations: PAC, proanthocyanidin; PO, per oral.

<sup>a</sup>Adjust for renal and metabolic function, formulations, allergies, prior culture data, antibiogram, etc.

prophylaxis, water is “safe, inexpensive, and does not select for antimicrobial resistance” [37]. A subsequent meta-analysis of 7 RCTs, including this one, found that increased fluid intake reduced the risk of cystitis recurrence at 6 months (odds ratio [OR], .13; 95% CI: .07–.25) but not at 12 months.

Pelvic floor physical therapy (PT) has also been shown to decrease the incidence of UTI in patients with incomplete voiding due to high-tone pelvic floor dysfunction (overly constricted muscles contributing to aberrant neural signaling and poor bladder emptying) [38]. In 1 study of 86 women with voiding dysfunction, those who were assigned to pelvic floor PT and/or biofeedback had a lower prevalence of UTI at 12 months than those in the control group (20%–25% vs 90%;  $P < .05$ ) [39].

Many prevention strategies for UTIs focus on perineal hygiene; however, there is little evidence to suggest that perineal hygiene contributes to UTI frequency. A study of 229 women demonstrated that there was no association between rUTI and pre- and postcoital voiding habits, wiping patterns, douching, use of hot tubs, frequent use of pantyhose or tights, or body mass index [14]. Indeed, perineal washing with antibacterial solutions has not been shown to prevent UTIs [40]. One perineal risk factor that has been associated with increased risk of rUTI is a urethral-to-anal distance of less than 4.5 cm [41], which is a nonmodifiable risk factor. Another modifiable risk factor is the use of spermicide. As such, spermicide use should be discouraged in patients with rUTIs [42]. Otherwise, clinicians should avoid perpetuating myths about behaviors contributing to rUTI and can instead educate patients with rUTI to reduce self-blame and non-evidence-based practices.

### Non-Antimicrobial Strategies

There are several non-antibiotic prevention strategies for rUTI, as shown in Table 1. In postmenopausal women who are not having an escalating frequency of infections, treatment with vaginal estrogen should be considered prior to initiating antibiotic prophylaxis. Genitourinary syndrome of menopause (GSM) is a constellation of symptoms that can include vaginal dryness, irritation, increased risk of incontinence, and UTIs. Vaginal estrogen therapy (VET) is currently recommended by the National Association of Menopause and confirmed in an independent systematic review as the gold standard for GSM treatment [43, 44]. Vaginal estrogen therapy is also recommended as part of the AUA/CUA/SUFU guidelines for the prevention of rUTI [6, 35, 45]. Vaginal estrogen therapy in all commercially available formulations has been shown to be effective in decreasing rUTI [46, 47]. Clinicians and patients may have concerns about the safety of vaginal estrogen due to the package insert. However, multiple studies have shown low systemic absorption [44]. A large, population-based study in approximately 50 000 breast cancer survivors has shown that VET did not increase mortality, and the American College of Obstetricians and Gynecologists confirms that VET may be used under a shared decision-making model in women with a history of breast cancer [48, 49]. Studies of the urinary microbiome show that 3–6 months of VET results in increased lactobacilli in the bladder microenvironment [50, 51]. Lactobacilli, specifically the species *Lactobacillus crispatus*, have been associated with urogenital health in preclinical studies.

Given preclinical mechanistic data, *Lactobacillus* probiotics have been studied in several trials, but currently lack data to

support their role [7]. However, several different species, routes, and dosing regimens were used, resulting in substantial heterogeneity of trials and overall low quality of evidence [52]. While it is still not clear if they may be helpful, if patients choose to take a probiotic, we would consider one containing *L. crispatus* as an active ingredient.

For premenopausal women, starting with antibiotic-sparing methods like methenamine or cranberry is preferable. Research indicates that both methenamine and cranberry products can effectively decrease the frequency of cystitis in females, with generally good tolerability and fewer side effects [53, 54]. The choice between them usually depends on patient and clinician preferences. Other commonly used antibiotic-sparing methods include D-mannose and probiotics. While not routinely recommended due to limited supporting data, they can serve as reasonable adjunctive options if patients choose to use them.

Methenamine is a non-antibiotic antiseptic strategy for the prevention of UTI, available in 2 formulations: hippurate or mandelate. These salts provide the acidic environment, where methenamine is hydrolyzed to ammonia and formaldehyde, which then act as bactericidal agents by denaturing bacterial proteins [54]. Due to the mechanism of action, bacteria cannot develop resistance to methenamine [55]. A 2012 Cochrane review showed that methenamine is effective in preventing UTIs [54], including in patients who require long-term catheterization [36]. More recently, a study showed that methenamine was as effective as trimethoprim prophylaxis in the prevention of rUTI [56]. This prescription medication is best utilized as a long-term prevention strategy and needs a minimum of 6–12 months to assess its efficacy in decreasing UTI recurrence [57].

Cranberry is a non-antibiotic option for the prevention of rUTIs in men and women of all ages. Proanthocyanidins (PACs), naturally occurring compounds in cranberries, are thought to prevent bacterial adherence to the bladder epithelium [58]. While large well-designed clinical trials examining cranberry supplements show conflicting results, the results of a recent Cochrane review supported the use of cranberry products in women with rUTI [6, 53]. Prior studies have shown that supplements must have 36 mg or more of soluble PACs to be effective [59]. It is important to counsel patients on these details, as supplements are not regulated via the US Food and Drug Administration (FDA) and effectiveness may be related to the potency and formulation of the cranberry supplement used.

D-Mannose is an inert monosaccharide that can be purchased over the counter and is popular with patients. Similar to cranberry, its metabolites are excreted into the urine and act to inhibit bacterial adhesion to the urothelium. While some meta-analyses have shown that D-mannose is comparable to daily antibiotic prophylaxis [60] in preventing UTIs, there is heterogeneity within the studies, which makes them difficult to compare. A 2022 Cochrane review was inconclusive as to

whether D-mannose is effective in preventing UTIs [61]. However, in a recent randomized clinical trial of 598 women, D-mannose did not reduce the incidence of rUTI [62].

While each of these agents have small effect sizes, using them in combination may achieve better results and allow for an antibiotic-sparing approach, with few adverse events.

#### Antibiotic Prevention Strategies

Antimicrobial prophylaxis has the most robust data for the prevention of rUTIs and is an excellent option for the properly selected and counseled patient. Generally, for pre- or postmenopausal women with escalating frequencies of infection, starting with antimicrobial prophylaxis and transitioning to non-antimicrobial strategies after several infection-free months can be considered.

- Postcoital prophylaxis. For women in whom sexual activity is a trigger for UTI, the use of postcoital antimicrobial prophylaxis has been shown to be safe and effective. Dosing after sexual intercourse may help reduce UTI recurrence while limiting adverse events associated with long-term antibiotics [6, 35].
- Low-dose continuous antibiotic prophylaxis is another option for patients with rUTI without a clear trigger. In the 2019 AUA guideline, 11 trials were reviewed that compared different antibiotics head-to-head. All antibiotics had a decreased likelihood of experiencing 1 or more UTI as compared with placebo (11 studies; relative risk [RR], .26; 95% CI: .18–.37;  $I^2 = 14\%$ ; absolute risk reduction [ARD], –46%; 95% CI: –56% to –37%) [63–72], with no significant differences between nitrofurantoin, fosfomycin, trimethoprim-sulfamethoxazole, norfloxacin, and cefaclor [71, 73–78]. Thus, the choice of prophylactic antibiotic depends on the local antibiogram, prior patient cultures, and tolerability of side effects. Given the FDA black box warning for tendon rupture with quinolones, they are not recommended as first-line daily prophylaxis [79]. The duration of therapy in most studies was 6–12 months, and patients generally returned to their baseline when discontinuing therapy.

While antibiotic prophylaxis has more extensive and consistent data supporting its efficacy, potential harms and adverse events related to prophylaxis must be weighed, especially in older adults. Antibiotics were associated with increased risk of any adverse event (6 studies; RR, 1.73; 95% CI: 1.08–2.79;  $I^2 = 0\%$ ; ARD, 12%; 95% CI: 1% to 22%) [6, 35, 64, 66–68, 70, 72] and vaginitis (3 studies; RR, 3.01; 95% CI: 1.27–7.15;  $I^2 = 0\%$ ; ARD, 18%; 95% CI: 5 to 32%). All antibiotics carry a risk of other side effects, such as gastrointestinal upset, skin rashes, and hepatic and renal toxicity, as well as medication interactions. No difference in the severity of adverse events was found between agents (4 studies; RR, 1.59; 95% CI: .58–4.42;

**Table 2. Proposed Model for Shared Decision-Making**

Shared Decision-Making Elements	Specific Considerations
Seek patient (and caregiver) participation	Weighing pros and cons, preferences, values
Explore and compare treatment options with your patient	Presenting risks and benefits of different options
Assess patient's values, treatment expectations, and preferences	Understanding the patient's goals of treatment
Decide with the patient and caregiver	Select a treatment option based on patient's treatment goals and preferences
Evaluate your shared decision	Assess the likelihood of desired outcome

$I^2 = 89\%$ ) [71, 74, 75, 77], so choice and duration of prophylactic antibiotic should be made considering patient-specific factors.

### Strategy Selection

Patients experiencing rUTIs have a diverse understanding of the disease pathology and a variety of distinct treatment goals [80]. Many patients do not know that uncomplicated cystitis typically is self-limited and rarely progresses to more severe disease [15, 63, 64]. Similarly, clinicians should not assume that all patients have the same goals of treatment but should ask open-ended questions to better understand the patient's treatment goals and expectations (eg, symptom resolution, risk of antibiotic resistance, risk of sepsis or ascending infection). Clinicians should consider a shared decision-making approach as there are a variety of options for rUTI prevention, different treatment goals, and the ratio of benefits to harms is "preference sensitive" [81]. A key component to the success of shared decision-making is agreement upon a shared goal of treatment. Table 2 summarizes shared decision-making elements to consider while deciding between antibiotic and non-antibiotic prevention strategies.

Clinicians should be honest about the expected outcomes of treatment so that a shared goal can be realistic, measurable, and attainable [82]. Wish/Worry statements can be helpful in framing these expectations—for example, "I wish we could completely get rid of your UTIs, but I worry that a realistic outcome is reducing you to about two infections per year." Another helpful strategy can be asking patients their greatest fears in continuing to have rUTIs. A patient whose greatest concern is recurrent hospitalization may have different goals than one who is distressed by a particular symptom [83]. Additionally, helping educate patients about asymptomatic bacteriuria and risks of antimicrobials can be essential to identifying a shared goal. When discussing the role of suppressive antimicrobial therapy, the risks of future resistant infections, antibiotic adverse effects, and risk of *Clostridioides difficile* infection (CDI) should be clearly highlighted. If jointly agreeing on a course of suppressive antibiotics, clinicians should a priori

define what outcomes would be defined as success and the timeline to reassess the risk/benefit of antibiotic suppression. While this approach can be time intensive upon the first visit, it establishes a strong foundation for a collaborative doctor–patient partnership moving forward.

### INDICATIONS FOR UROGYNECOLOGIST OR UROLOGIST REFERRAL

Most patients with recurrent uncomplicated UTI may be treated successfully by primary care physicians. Urogynecologist referral for rUTI is indicated when risk factors for complicated UTI are present (anatomical or physiologic abnormalities of the urinary tract), when a surgically correctable cause of UTI is suspected, or when the diagnosis of UTI as a cause for recurrent lower urinary tract symptoms is uncertain.

### FOLLOW-UP AND MONITORING

Patients with rUTI should be periodically assessed for the effectiveness of their prevention strategies. However, in the absence of distinct UTI symptoms, UA and urine culture should not be routinely collected [6, 35] as this can lead to the identification of asymptomatic bacteriuria and overtreatment with antibiotics if the bacteriuria is treated. Behavioral and non-antibiotic prevention strategies, in particular VET, need 3–6 months to reach full benefit. It is beneficial to follow-up within a few weeks of initiating prophylaxis to assess compliance, adverse events, or need to adjust strategy.

The duration of antibiotic prophylaxis in the literature ranges from 4 to 12 months. In clinical practice, the duration of prophylaxis can be variable, from 3 to 6 months to 1 year, with periodic assessment and monitoring. Some women stay on continuous or postcoital prophylaxis for years to maintain the benefit without adverse events.

There is emerging evidence that disruptions in the urinary microbiome contribute to rUTI [84, 85]. It can take 3–6 months to restore the microbiome after antibiotic treatment, so an appreciation for this broader time frame can often reassure patients who are frustrated with a series of rUTIs in close proximity. The goal is to partner with patients and develop an individualized treatment and prevention plan, and once the cycle of rUTI is broken, one can reassess in 6–12 months for continuation or discontinuation of prescription medications. As such, shared decision-making should be used to determine when to stop antimicrobial prophylaxis or if continuing daily prophylaxis is in the benefit of the patient and their goals.

### EMERGING DIAGNOSTICS AND THERAPIES

There is increasing interest in exploring new methods for rapidly identifying and treating rUTI episodes. Molecular testing, such as polymerase chain reaction (PCR) and next-generation

sequencing (NGS), shows promise in providing comprehensive information about genitourinary microbes. While these tests may improve the identification of bacteria, they have the potential to increase the diagnosis of asymptomatic bacteriuria. Hence, caution is needed before widespread adoption due to potential antibiotic overuse [28].

Similarly, investigators continue to look for new, non-antibiotic treatment and prevention options for rUTI. Immunomodulating agents such as antibacterial vaccines have been studied since the 1990s, predominantly in female populations with rUTI [86]. The earliest iterations of vaccines had variable results. Newer iterations of vaccines utilize polyvalent heat-killed bacterial preparations. One such vaccine, called MV140 (Uromune®, Immunotek S.L., Spain), has been studied in cohort studies and 1 randomized trial, suggesting beneficial effects that last for 6 months. Robust randomized trials are needed to understand if this vaccine is effective, and how often it may need to be re-dosed.

Another emerging therapy for rUTI involves bacteriophages, also referred to as phage therapy [87]. Bacteriophages are viruses that infect bacteria, resulting in quick bacterial cell death, thereby “re-shaping” the bacterial populations in an environment [88]. Custom bacteriophage preparations have been studied in 7 instances of complicated UTI with positive results, few side effects, and complete resolution of infections for up to 6 months [89]. Bacteriophages are specific to bacterial strains, and mass-produced products that are available “off-the-shelf” may have vastly different results than phage cocktails that are customized for a specific infection. However, there may be a role for phage cocktails in the treatment of recalcitrant infections, complicated rUTIs, or instances of colonization with multidrug-resistant bacteria [90].

Fecal microbiota transplantation (FMT) has been studied as a therapy for recurrent CDI. Many patients with CDI also have rUTI, and an incidental finding in early FMT studies was that rUTI improved concurrent with improvements in CDI. Follow-up studies have been limited by small sample sizes or retrospective study designs, without strong conclusions [91, 92]. There are now 2 FMT products approved by the US FDA for clinical use in CDI [93]. Further studies are needed to determine whether these are truly effective for UTI prevention in the absence of CDI.

## Notes

**Acknowledgments.** We would like to thank Hilary Stoddard for her assistance with graphic design for all figures.

**Financial support.** S. D. A. was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK grant number K12DK100024) for this work.

**Potential conflicts of interest.** Dr Advani reports support from Centers for Disease Control and Prevention (SHEPherD 75D30121D12733-D5-E003 and 5U54CK000616-02), the Society for Healthcare Epidemiology of America, and the Duke Claude D. Pepper Older Americans Independence Center (National Institute on Aging grant no.

P30AG028716), as well as past consulting fees from Locus Biosciences, Sysmex America, GlaxoSmithKline, bioMérieux, and the Infectious Diseases Society of America. Dr. Advani became an employee of GSK/ViiV Healthcare after submission of this manuscript. Dr. Siddiqui reports ongoing research support from Medtronic, Inc. and Ethicon Johnson & Johnson, consulting fees from Boston Scientific, royalties from UpToDate, and serves on the Board of Directors for the American Urogynecologic Society. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Suskind AM, Saigal CS, Hanley JM, et al. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. *Urology* **2016**; 90:50–5.
- Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. *Ther Adv Urol* **2019**; 11:1756287219832172.
- Peck J, Shepherd JP. Recurrent urinary tract infections: diagnosis, treatment, and prevention. *Obstet Gynecol Clin North Am* **2021**; 48:501–13.
- Brubaker L, Carberry C, Nardos R, Carter-Brooks C, Lowder JL. American Urogynecologic Society best-practice statement: recurrent urinary tract infection in adult women. *Female Pelvic Med Reconstr Surg* **2018**; 24:321–35.
- Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. *BMJ* **2013**; 346:f3140.
- Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. *J Urol* **2019**; 202:282–9.
- Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. *Nat Rev Urol* **2018**; 15:750–76.
- Ellis AK, Verma S. Quality of life in women with urinary tract infections: is benign disease a misnomer? *J Am Board Fam Pract* **2000**; 13:392–7.
- Ennis SS, Guo H, Raman L, Tambyah PA, Chen SL, Tiong HY. Premenopausal women with recurrent urinary tract infections have lower quality of life. *Int J Urol* **2018**; 25:684–9.
- Thomas-White K, Navarro P, Wever F, King L, Dillard LR, Krapf J. Psychosocial impact of recurrent urogenital infections: a review. *Womens Health (Lond)* **2023**; 19:17455057231216537.
- Foxman B. Recurring urinary tract infection: incidence and risk factors. *Am J Public Health* **1990**; 80:331–3.
- Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. *Am J Epidemiol* **2000**; 151:1194–205.
- Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. *Clin Infect Dis* **1996**; 22:91–9.
- Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. *J Infect Dis* **2000**; 182: 1177–82.
- Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. *N Engl J Med* **1996**; 335: 468–74.
- Hawn TR, Scholes D, Li SS, et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. *PLoS One* **2009**; 4:e5990.
- O’Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. *BMC Infect Dis* **2011**; 11:200.
- Boris S, Suarez JE, Vazquez F, Barbes C. Adherence of human vaginal lactobacilli to vaginal epithelial cells and interaction with uropathogens. *Infect Immun* **1998**; 66:1985–9.
- Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med* **2012**; 366:1028–37.
- Neugent ML, Hulyalkar NV, Nguyen VH, Zimmern PE, De Nisco NJ. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. *mBio* **2020**; 11:e00218-20.
- Lewis AL, Gilbert NM. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. *GMS Infect Dis* **2020**; 8:doc02.
- Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. *Nat Rev Microbiol* **2020**; 18:211–26.
- Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. *PLoS Med* **2007**; 4:e329.
- Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a

- 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* **2011**; 52:e103–20.
25. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. *Clin Infect Dis* **2019**; 68:1611–5.
  26. Food and Drug Administration. Development considerations of antimicrobial drugs for the treatment of uncomplicated urinary tract infections (UTI). Available at: <https://www.fda.gov/drugs/news-events-human-drugs/development-considerations-antimicrobial-drugs-treatment-uncomplicated-urinary-tract-infections-uti#:~:text=The%20Food%20and%20Drug%20Administration,discuss%20nonclinical%20and%20clinical%20considerations>. Accessed 3 June 2023.
  27. Advani SD, North R, Turner NA, et al. Performance of urinalysis parameters in predicting urinary tract infection: does one size fit all? *Clin Infect Dis* **2024**; 79(3):600–3.
  28. Anger JT, Bixler BR, Holmes RS, Lee UJ, Santiago-Lastra Y, Selph SS. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. *J Urol* **2022**; 208:536–41.
  29. Advani SD, Turner NA, North R, et al. Proposing the “Continuum of urinary tract infection (UTI)” for a nuanced approach to diagnosis and management of UTIs. *J Urol* **2024**; 211:690–8.
  30. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. *N Engl J Med* **2013**; 369:1883–91.
  31. Vasudeva P, Madersbacher H. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: some revered, few forgotten, others ignored. *NeuroUrol Urodyn* **2014**; 33:95–100.
  32. Merritt JL. Residual urine volume: correlate of urinary tract infection in patients with spinal cord injury. *Arch Phys Med Rehabil* **1981**; 62:558–61.
  33. Corse TD, Rahmani LD, Hasley HL, Kim K, Harrison R, Fromer DL. New avenue of diagnostic stewardship: procedural stewardship for recurrent urinary tract infections in female patients. *Antimicrob Steward Healthc Epidemiol* **2023**; 3:e231.
  34. Vincent YM, Frachon A, Buffeteau C, Conort G. Construction of a patient decision aid for the treatment of uncomplicated urinary tract infection in primary care. *BMC Fam Pract* **2021**; 22:26.
  35. Bixler BR, Anger JT. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. *J Urol* **2022**; 208:754–6.
  36. Stair SL, Palmer CJ, Lee UJ. Evidence-based review of nonantibiotic urinary tract infection prevention strategies for women: a patient-centered approach. *Curr Opin Urol* **2023**; 33:187–92.
  37. Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. *JAMA Intern Med* **2018**; 178:1509–15.
  38. De Paepe H, Hoebeke P, Renson C, et al. Pelvic-floor therapy in girls with recurrent urinary tract infections and dysfunctional voiding. *Br J Urol* **1998**; 81(Suppl 3):109–13.
  39. Minardi D, d’Anzeo G, Parri G, et al. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study. *Urology* **2010**; 75:1299–304.
  40. Cass AS, Ireland GW. Antibacterial perineal washing for prevention of recurrent urinary tract infections. *Urology* **1985**; 25:492–4.
  41. Hooton TM, Stapleton AE, Roberts PL, et al. Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. *Clin Infect Dis* **1999**; 29:1600–1.
  42. Cai T. Recurrent uncomplicated urinary tract infections: definitions and risk factors. *GMS Infect Dis* **2021**; 9:doc03.
  43. North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. *Menopause* **2022**; 29:767–94.
  44. Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. *Menopause* **2019**; 26:431–53.
  45. Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. *Female Pelvic Med Reconstr Surg* **2021**; 27:112–7.
  46. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. *Obstet Gynecol* **2014**; 124:1147–56.
  47. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev* **2008**; 2:CD005131.
  48. McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. *JAMA Oncol* **2024**; 10:103–8.
  49. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. *Obstet Gynecol* **2021**; 138:950–60.
  50. Thomas-White K, Taega S, Limeira R, et al. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms. *Am J Obstet Gynecol* **2020**; 223:727.e1–e11.
  51. Jung CE, Estaki M, Chopyk J, et al. Impact of vaginal estrogen on the urobiome in postmenopausal women with recurrent urinary tract infection. *Female Pelvic Med Reconstr Surg* **2022**; 28:20–6.
  52. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. *Cochrane Database Syst Rev* **2015**; 2015:CD008772.
  53. Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev* **2023**; 11:CD001321.
  54. Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. *Cochrane Database Syst Rev* **2012**; 10:CD003265.
  55. Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. *Expert Rev Anti Infect Ther* **2014**; 12:549–54.
  56. Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. *Int Urogynecol J* **2022**; 33:571–80.
  57. Kale S, Somani BK. The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women—a systematic review. *Curr Opin Urol* **2023**; 33:488–96.
  58. Ermel G, Georgeault S, Isisan C, Besnard M. Inhibition of adhesion of uropathogenic Escherichia coli bacteria to uroepithelial cells by extracts from cranberry. *J Med Food* **2012**; 15:126–34.
  59. Howell AB, Botto H, Combesure C, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. *BMC Infect Dis* **2010**; 10:94.
  60. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. *Am J Obstet Gynecol* **2020**; 223:265.e1–e13.
  61. Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. *Cochrane Database Syst Rev* **2022**; 8:CD013608.
  62. Hayward G, Mort S, Hay AD, et al. d-Mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial. *JAMA Intern Med* **2024**; 184(6):619–28.
  63. Bailey RR, Roberts AP, Gower PE, De Wardener HE. Prevention of urinary-tract infection with low-dose nitrofurantoin. *Lancet* **1971**; 2:1112–4.
  64. Gower PE. The use of small doses of cephalixin (125 mg) in the management of recurrent urinary tract infection in women. *J Antimicrob Chemother* **1975**; 1(3 Suppl):93–8.
  65. Kranjčec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. *World J Urol* **2014**; 32:79–84.
  66. Martens MG, Finkelstein LH. Daily cinoxacin as prophylaxis for urinary tract infections in mature women: a prospective trial. *Adv Ther* **1995**; 12:207.
  67. Martorana G, Giberti C, Damonte P. Preventive treatment of recurrent cystitis in women. Double-blind randomized study using cinoxacin and placebo. *Minerva Urol Nefrol* **1984**; 36:43–9.
  68. Nicolle LE, Harding GK, Thompson M, Kennedy J, Urias B, Ronald AR. Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women. *Antimicrob Agents Chemother* **1989**; 33:1032–5.
  69. Rugendorff E, Haralambie E. Low-dose norfloxacin versus placebo for long-term prophylaxis of recurrent uncomplicated urinary tract infection. *Chemioterapia* **1987**; 6:533–5.
  70. Scheckler WE, Burt RA, Paulson DF. Comparison of low-dose cinoxacin therapy and placebo in the prevention of recurrent urinary tract infections. *J Fam Pract* **1982**; 15:901–4.
  71. Stamm WE, Counts GW, Wagner KF, et al. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. *Ann Intern Med* **1980**; 92:770–5.
  72. Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. *JAMA* **1990**; 264:703–6.
  73. Brumfit W, Hamilton-Miller JMT. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. *Infection* **1995**; 23:98–102.

74. Brumfitt W, Hamilton-Miller JM, Smith GW, al-Wali W. Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrochantin) in the prophylaxis of recurrent urinary tract infection in women. *Q J Med* **1991**; 81:811–20.
75. Brumfitt W, Smith GW, Hamilton-Miller JM, Gargan RA. A clinical comparison between Macrochantin and trimethoprim for prophylaxis in women with recurrent urinary infections. *J Antimicrob Chemother* **1985**; 16:111–20.
76. Mozdzan M, Ruxer J, Siejka A, Loba J, Markuszewski L. The efficacy of chronic therapy of recurrent lower urinary tract infections with fosfomycin and nitrofurantoin in type 2 diabetic patients. *Adv Clin Exp Med* **2007**; 16:777.
77. Nunez U, Solis Z. Macrocrystalline nitrofurantoin versus norfloxacin as treatment and prophylaxis in uncomplicated recurrent urinary tract infection. *Curr Ther Res* **1990**; 48:234–45.
78. Seppanen J. Cinoxacin vs trimethoprim—safety and efficacy in the prophylaxis of uncomplicated urinary tract infections. *Drugs Exp Clin Res* **1988**; 14:669–71.
79. Bove C, Baldock RA, Champigneulle O, Martin L, Bennett CL. Fluoroquinolones: old drugs, putative new toxicities. *Expert Opin Drug Saf* **2022**; 21:1365–78.
80. Pat JJ, Aart TVD, Steffens MG, Witte LPW, Blanker MH. Assessment and treatment of recurrent urinary tract infections in women: development of a questionnaire based on a qualitative study of patient expectations in secondary care. *BMC Urol* **2020**; 20:190.
81. Hargraves IG, Fournier AK, Montori VM, Bierman AS. Generalized shared decision making approaches and patient problems. Adapting AHRQ's SHARE approach for purposeful SDM. *Patient Educ Couns* **2020**; 103:2192–9.
82. McNaughton EC, Curran C, Granskie J, et al. Patient attitudes toward and goals for MDD treatment: a survey study. *Patient Prefer Adherence* **2019**; 13:959–67.
83. Comer A, Fettig L, Torke AM. Identifying goals of care. *Med Clin North Am* **2020**; 104:767–75.
84. Schneeweiss J, Koch M, Umek W. The human urinary microbiome and how it relates to urogynecology. *Int Urogynecol J* **2016**; 27:1307–12.
85. Drake MJ, Morris N, Apostolidis A, Rahnama'i MS, Marchesi JR. The urinary microbiome and its contribution to lower urinary tract symptoms; ICI-RS 2015. *Neurourol Urodyn* **2017**; 36:850–3.
86. Mak Q, Greig J, Dasgupta P, Malde S, Raison N. Bacterial vaccines for the management of recurrent urinary tract infections: a systematic review and meta-analysis. *Eur Urol Focus* **2024**; 10(5):761–9.
87. Kim P SA, Kime JC et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to *Escherichia coli* (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. *Lancet Infect Dis* **2024**; 24: 1319–1332.
88. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. *Bacteriophage* **2011**; 1:31–45.
89. Uyttbroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. *Lancet Infect Dis* **2022**; 22: e208–20.
90. Le T, Nang SC, Zhao J, et al. Therapeutic potential of intravenous phage as stand-alone therapy for recurrent drug-resistant urinary tract infections. *Antimicrob Agents Chemother* **2023**; 67:e0003723.
91. Jeney SES, Avelar-Barragan J, Whiteson K, Chang J, Dutta S, Lane F. Fecal putative uropathogen abundance and antibiotic resistance gene carriage in women with refractory recurrent urinary tract infection treated with fecal microbiota transplantation. *Female Pelvic Med Reconstr Surg* **2022**; 28:213–9.
92. Wood N, Propst K, Yao M, Ferrando CA. Fecal Microbiota transfer for *Clostridium difficile* infection and its effects on recurrent urinary tract infection. *Urogynecology (Phila)* **2023**; 29:814–26.
93. Food and Drug Administration. Fecal microbiota products. Available at: <https://www.fda.gov/vaccines-blood-biologics/fecal-microbiota-products>. Accessed 20 May 2024.